Immunomodulating activity of rifampicin

Journal of Chemotherapy

Volumn 16, Issue 4, 2004, Pages 357-361

  Ziglam, H M ^a   Daniels, I ^b   Finch, R G ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Immunomodulation; Interleukin 1beta; Monocytes; Rifampicin; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PANSORBIN; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MALE; MONOCYTE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STAPHYLOCOCCUS;

EID: 3943108105     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.4.357     Document Type: Article

References (22)

1. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429(1-3): 209-29.
2. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3(6): 359-71.
3. Labro MT. Interference of antibacterial agents with phagocyte functions, immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 2000; 13(4): 615-50.
4. Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13(1): 3-8.
5. Cohen J, Abraham E. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 1999; 180(1): 116-21.
6. Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998; 27(6): 1497-507.
7. Rodriguez JL, Miller CG, DeForge LE, Kelty L, Shanley CJ, Bartlett RH, et al. Local production of interleukin-8 is associated with nosocomial pneumonia. J Trauma 1992; 33(1): 74-81; discussion 81-2.
8. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiforc, TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumoniae. Infect Immun 1996; 64(12): 5211-8.
9. Laichalk LL, Bucknell KA, Huffnagle GB, Wilkowski JM, Moore TA, Romanelli RJ, et al. Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect Immun 1998; 66(6): 2822-6.
10. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection 1996; 24(4): 275-91.
11. Giuliani A, Porcelli SA, Tentori L, Graziani G, Testorelli C, Prete SP, et al. Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen. Life Sci 1998; 63(12): 985-94.
12. Tentori L, Graziani G, Porcelli SA, Sugita M, Brenner MB. Madaio R, et al. Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrob Agents Chemother 1998; 42(3): 550-4.
13. Gollapudi S, Jaidka S, Gupta S. Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J Clin Immunol 2003; 23(1): 11-22.
14. Duncker D, Ullmann U. Influence of various antimicrobial agents on the chemiluminescence of phagocytosing human granulocytes. Chemotherapy 1986; 32(1): 18-24.
15. Martinez Oliva C, Puente Ranz LF, Gonzalez Roiz C, Munoz Sanz A, Blanco Palenciano J, Blanco Roca MT, et al. [Isoniazid and pyrazinamide: in vitro effect on polymorphonuclear leukocytes]. Sangre (Barc) 1987; 32(5): 455-62.
16. Zeis BM. Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro. Chemotherapy 1-988; 34(1): 56-60.
17. Demkow U, Malkowska-Zwierz W, Rogala E, Skopinska-Rozewska E, Lewandowski Z. Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes. Folia Biol (Praha) 1995; 41(5): 257-62.
18. Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int Immunopharmacol 2003; 3(4): 513-22.
19. Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 2002; 49(3): 531-4.
20. Caruso I, Montrone F, Fumagalli M, Vernazza M, Santandrea S. Rheumatoid knee synovitis successfully treated with intraarticular Rifamicin SV. Arthritis Rheum 1980; 23(4): 518-9.
21. Caruso I, Principi N, D'Urbino G, Santandrea S, Boccassini L, Montrone F, et al. Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis. J Int Med Res 1993; 21(5): 243-56.
22. Radossi P, Baggio R, Petris U, De Biasi E, Risato R, Davoli PG, et al. Intra-articular rifamycin in haemophilic arthropathy. Haemophilia 2003; 9(1): 60-3.